Summary
- Profile Type
- Business Offer
- POD Reference
- BOIL20230222019
- Term of Validity
- 22 February 2023 - 21 February 2025
- Company's Country
- Israel
- Type of partnership
- Commercial agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- An Israeli company specializing in rapid diagnostic solutions to the point-of-care (POC) and for self-testing has developed an innovative integrated platform and device for rapid diagnostic testing. Advantages include: single-step performance, high efficiency, easy-to-use. The targeted partners are agents, representatives, distributors, and manufacturers in the diagnostics field. The company is looking for a commercial agency, distribution services, or joint venture agreement.
- Full Description
-
This Israeli company was founded in 2004 with a business focus of providing rapid diagnostic solutions to the point-of-care (POC) and for self-testing. The company develops and manufactures its product in an ISO13485:2016 approved facility, and markets a wide variety of rapid diagnostic tests (RDT), leading in their adoption as first-line screening tools for physicians and patients. The company was the first to introduce rapid tests for strep A (group A streptococcus) diagnoses to Israeli pharmacies in 2004, allowing patients to purchase these tests over-the-counter (OTC) prior to visiting their primary care physician. This improved patient screening at the physician’s office, thus reducing antibiotic abuse, since a negative strep A result would enable doctors to avoid the administration of antibiotics to patients without a strep A infection. An additional goal was to shift strep A screening from centralized labs to the local point-of-care, improving HMO service when the centralized lab was inoperative (e.g., on weekends) or overloaded. The company’s rapid diagnostic tests (RDT) cover most common diseases and healthcare concerns, including: infectious disease, fertility, early markers of certain diseases, urinalysis and urinary tract infections, drug abuse, etc. Customers in Israel include all major HMOs, major hospitals, military, police, pharmacies and pharma sale networks, private clinics, and medical centers. Of the estimated two million strep A tests annually performed in Israel, around 25% are RDT, thereby validating the chosen business model based on patients assuming responsibility for their own health first, followed by ENT (otolaryngology) and family physicians' adoption and acceptance of strep A RDT as a reliable, first-line diagnostic standard.
The company is currently marketing its first-of-its-kind, simple-to-use, innovative device, which provides an integrated platform for additional, single-step swab-based rapid diagnostic test development.
Applying this new platform to strep A diagnosis reduces performance complexity to a single step, eliminating the need for reagent mixing and dispensing, thereby making it simpler and faster to use. The offered test is popular and used at the physician’s office, allowing the healthcare professional to focus on the patient rather than dealing with cumbersome test performance steps and procedures.
The strep A diagnostic device is CE-marked and approved by the Israeli Ministry of Health, and is currently distributed in Israel and Europe. It has replaced the previous 3-step RDT product, being sold directly to patients and physicians through Israeli pharmacies. The test is widely adopted by ENT and family physicians.
The company is constantly expanding its product line by improving its existing products and adding new ones to its portfolio. It is seeking distributors/agents/representatives for its current products (commercial agency, distribution services agreements) and original equipment manufacturers (OEM) of diagnostic products to co-develop additional applications for the core technologies under a joint venture agreement. - Advantages and Innovations
-
Innovative device, platform, and proprietary swab for a single-step swab-based RDT integrating all components necessary to perform tests, with the following advantages:
1) improving sample collection
2) showing higher pathogen recovery efficacy
3) RDT simplification by minimizing the number of kit components
4) reducing performance complexity to a one-step operation
5) increasing RDT usability and adoption by untrained healthcare providers
6) providing improved RDT accuracy
7) test results available during in-patient visit
8) minimal liquid waste disposal
While RDTs for strep A infection diagnosis existed on the market for over 20 years, their widespread use by physicians and laboratories has been hampered by their relative operational complexity, requiring laborious and precise reagent dispensing and mixing for accurate disease diagnosis - Stage of Development
- Already on the market
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
Partner Sought
- Expected Role of a Partner
-
Distributor/agent/representative specializing in medical devices/diagnostics, having corresponding connections with hospitals, pharmacies, clinics, HMOs, etc. The distributer's role would be to help connect the company to local customers.
-and/or-
Original equipment manufacturers (OEM) of diagnostic products. Manufacturers' role would be to co-develop additional applications for core technologies under a joint venture agreement. - Type and Size of Partner
- Other
- SME <=10
- SME 50 - 249
- SME 11-49
- Type of partnership
- Commercial agreement
Dissemination
- Technology keywords
- 06005004 - Remote diagnostics
- 06001012 - Medical Research
- 06002007 - In vitro Testing, Trials
- 06001005 - Diagnostics, Diagnosis
- 006001007 - Diseases
- Market keywords
- 05001002 - In-vitro diagnostics
- 05001001 - Diagnostic services
- 05004005 - Diagnostic equipment
- 05007005 - Hospital and other institutional management
- 005001008 - Diagnostic test products and equipment
- Targeted countries
- All countries